Health Care-Related Economic Burden of the Polycystic Ovary Syndrome during the Reproductive Life Span
The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index.
Abstract
CONTEXT: The polycystic ovary syndrome (PCOS) is the most common endocrine abnormality of reproductive-aged women today, affecting approximately 6.6% of unselected reproductive-aged women (approximately 4 million women in the United States) (1990 National Institutes of Health criteria), and potentially represents a significant financial burden to our health care. OBJECTIVE: The objective of the study was to define, using current definitions and prevalence or incidence data, the minimal economic burden that PCOS in reproductive-aged women represents for the United States. DESIGN: The study design was a literature review. SETTING: The study was conducted at a tertiary care center. PATIENTS OR OTHER PARTICIPANTS: There were no patients or other participants. INTERVENTION(S): We performed a systematic review of the published medical literature to identify studies evaluating epidemiology of reproductive-age PCOS and its clinical consequences and costs. We tied general societal cost data for the different health consequences to reproductive-age PCOS costs, using prevalence data. MAIN OUTCOME MEASURE(S): The main measure in the study was total health care-related economic costs. RESULTS: We estimated the mean annual cost of the initial evaluation to be dollar 93 million (2.1% of total costs), that of hormonally treating menstrual dysfunction/abnormal uterine bleeding to be dollar 1.35 billion (31.0% of total), that of providing infertility care to be dollar 533 million (12.2% of total), that of PCOS-associated diabetes to be dollar 1.77 billion (40.5% of total), and that of treating hirsutism to be dollar 622 million (14.2% of total). CONCLUSIONS: The total cost of evaluating and providing care to reproductive-aged PCOS women in the United States is dollar 4.36 billion. Because the cost of the diagnostic evaluation accounted for a relatively minor part of the total costs (approximately 2%), more widespread and liberal screening for the disorder appears be a cost-effective strategy, leading to earlier diagnosis and intervention and possibly the amelioration and prevention of serious sequelae.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“comprehensive screening and counseling from physicians and greater public awareness can curtail morbidity and reduce the economic burden on both the patient and the healthcare system.”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“PCOS has a high healthcare-related economic burden”
From 'I'm usually being my own doctor': women's experiences of managing polycystic ovary syndrome in Canada (2023) · cites this paper as [61]
In the citing paper
“Also from a resource allocation perspective, the financial costs related to diagnosis of PCOS are only a small fraction (2%) of the total costs associated with comprehensive care for PCOS in the United States (32).”
From Delayed Diagnosis and a Lack of Information Associated With Dissatisfaction in Women With Polycystic Ovary Syndrome (2016) · cites this paper as [32]
Citations
Cites
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
The Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712
Self-citationMen at risk: occupation and male infertility
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,387
Amenorrhea associated with bilateral polycystic ovaries
Stein, I. F., & Leventhal, M. L. (1935) · American Journal of Obstetrics and Gynecology · doi:10.1016/s0002-9378(15)30642-6 · Cited by 2,121
Legro, R. S. (1999) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.84.1.165 · Cited by 1,743
Knochenhauer, E. S., Key, T. J., Kahsar-Miller, M., Waggoner, W., Boots, L. R., & Azziz, R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.9.5090 · Cited by 1,516
Self-citationAsunción, M., Calvo, R. M., San Millán, J. L., Sancho, J., Avila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,318
Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.
Ehrmann, D. A., Barnes, R. B., Rosenfield, R. L., Cavaghan, M. K., & Imperial, J. (1999) · Diabetes Care · doi:10.2337/diacare.22.1.141 · Cited by 1,257
Androgen Excess in Women: Experience with Over 1000 Consecutive Patients
Azziz, R., Sanchez, L. A., Knochenhauer, E. S., Moran, C., Lazenby, J., Stephens, K. C., Taylor, K., & Boots, L. R. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031122 · Cited by 1,132
Self-citation
Cited by
Items 501–556 of 556
AGS – PCOS und ästhetische Endokrinologie
Seufert, R. (2023) · Springer eBooks · doi:10.1007/978-3-662-65371-5_5
Ethics of Existing Treatment of Polycystic Ovary SyndromePreprint
Halapeti, S. (2023) · doi:10.58445/rars.269
Banu, H., & Razick, J. (2019) · Zenodo (CERN European Organization for Nuclear Research) · doi:10.5281/zenodo.2586428
Prevalence and Phenotypic Diversity of PCOS in Indian Women: An Observational Study
Khanorkar, N., Kulkarni, P., & Warjukar, E. (2023) · International Journal of Science and Research (IJSR) · doi:10.21275/sr231005091135
Li, R., Zhang, L., & Liu, Y. (2024) · Research Square · doi:10.21203/rs.3.rs-4260677/v1
The Correlation Between Abnormal Uterine Bleeding in Early Menarche and PCOS Later in Adolescence
Deligeoroglou, E., & Karountzos, V. (2024) · ISGE series · doi:10.1007/978-3-031-55300-4_4
Ghoneim, B. M., EL-Gharib, M. N., El-Badry, A. M., & Farahat, M. A. (2024) · Tanta Medical Journal · doi:10.4103/tmj.tmj_10_21
Choudhary, A., Singh, P., Agarwal, S., Saxena, N., & Bahuguna, N. (2024) · Journal of South Asian Federation of Obstetrics and Gynaecology · doi:10.5005/jp-journals-10006-2457
Polycystic Ovarian Syndrome (PCOS), Underlying Factors and Potential Treatments
Ghafoor, N., Tariq, Z., Azmat, R., JAVED, K., TAHIR, A., KHALIL, M., NAEEM, A., & AAMIR, U. (2024) · doi:10.61748/zool.2024/01
Sex differences in cardiovascular, renal, and metabolic responses to androgens
Cardozo, L. L. Y., Rezq, S., Reckelhoff, J. F., & Romero, D. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-22266-5.00001-x
Polycystic Ovarian Disease: Current Insights and therapeutic Strategies
Shakya, S. (2024) · African Journal of Biomedical Research · doi:10.53555/ajbr.v27i4s.4760
Shah, S., Sharma, D. A., Ojha, S., & Debnath, M. (2024) · Journal of Datta Meghe Institute of Medical Sciences University · doi:10.4103/jdmimsu.jdmimsu_544_24
To Study the PCOS (Polycystic Ovary Syndrome)
Khadse, M. S. V., Chavhan, M. R. U., & Kitukale, M. D. (2025) · International Journal of Advanced Research in Science Communication and Technology · doi:10.48175/ijarsct-23068
Exposição a desreguladores endócrinos e síndrome dos ovários policísticos : uma revisão sistemática
Abreu, C. R. D. C. (2017) · RIUnB Institutional Repository (University of Brasília) · doi:10.26512/2017.08.d.24892
A Systematic Approach to Menstrual Tracking: Proposed Methodology and Design
Khadse, C., & Mendhe, S. (2025) · International Conference on Intelligent Sustainable Systems (ICISS) · doi:10.1109/iciss63372.2025.11076209
Need to address the root cause of Polycystic ovary syndrome (PCOS)
Vihari, J., Sriteja, N., Sahu, S., Das, C., Dalai, S. P., Tripathy, D., Dash, A. P., Pooja, U., Maiti, S., & Samal, S. (2023) · Medicine India · doi:10.25259/medindia_20_2022
CLINICAL PROFILE AND OUTCOMES OF PATIENTS WITH POLYCYSTIC OVARIAN SYNDROME
Poonia, M. (2025) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.53555/6vtsz040
Sowmya, A. S. (2025) · International Journal of Zoology and Applied Biosciences · doi:10.55126/ijzab.2025.v10.i05.003
Frequency of Polycystic Ovarian Syndrome in Women Presenting with Infertility
Hanifa, H., Shoaib, M., Achakzai, M., Munir, U., Khan, M., Sanam, M., & Naeem, S. (2025) · Indus journal of bioscience research. · doi:10.70749/ijbr.v3i2.2476
Umeche, I. E., Olaniyan, M. F., Olawuyi, A. O., Umeche, U. C., & Nwoka, N. C. (2026) · Yemen Journal of Medicine · doi:10.63475/yjm.v5i1.0287
“[19]”
Ganie, M. A., Wani, I. A., & Arif, T. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898810931125010006
Hoque, A., Uddin, M. R., & Karmakar, P. (2025) · Journal of Chittagong Medical College Teachers Association · doi:10.3329/jcmcta.v35i2.84654
Experiences of Women with Polycystic Ovarian Syndrome: A Qualitative Inquiry
Bashir, A., Bhat, N., Jan, M., Shakeel, A., Ahmed, S., Altaf, M. M., & Nazir, I. (2025) · Women s Reproductive Health · doi:10.1080/23293691.2025.2593855
Zhao, J., Ketlhoafetse, A., Liu, X., & Cao, Y. (2022) · Figshare · doi:10.6084/m9.figshare.20001138
García-Beltrán, C., Malpique, R., Andersen, M. S., Bas, F., Bassols, J., Darendelıler, F., Díaz, M., Dieris, B., Fanelli, F., Fröhlich-Reiterer, E. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24151127
García-Beltrán, C., Malpique, R., Andersen, M. S., Baş, F., Bassols, J., Darendelıler, F., Díaz, M., Dieris, B., Fanelli, F., Fröhlich-Reiterer, E. E., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24151124
Polycystic ovary syndrome – burden and adverse outcomes
Subramanian, A. (2023) · University of Birmingham Institutional Research Archive (University of Birmingham)
Is metformin an effective adjunctive treatment in treating hirsutism in patients with PCOS?
Alspach, M. (2021) · Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine)
Metabolic health outcomes among women with polycystic ovary syndrome
Kumarendran, B. (2024) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 3
Addressing Gaps in Knowledge on Polycystic Ovary Syndrome in Canada
Patrick, H., McAlister, L., Badesha, J., & Pourtousi, A. (2024) · Scholarship@Western (Western University)
Das Polyzystische Ovarialsyndrom : eine szientometrische Analyse
Berges, L. (2021) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt)
Gurule, S. C. (2023) · OakTrust (Texas A&M University Libraries)
Cavalcante, D. C. B. (2023) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Lu, X., Lim, E. C. N., Zeng, G., Lim, C. E. D., & Zeng, L. (2026) · Frontiers in Reproductive Health · doi:10.3389/frph.2025.1748768
“This condition imposes substantial economic and societal burdens (3), manifesting as a systemic and heterogeneous disorder characterized by sporadic ovulation or anovulation, polycystic ovary morphology (PCOM), and clinical or biochemical signs of hyperandrogenism (HA), including dysmenorrhea,…”
Natarajan, M., Shweatha, H. E., & Nataraj, R. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1766838 · Cited by 1
A Lifecourse Perspective on Polycystic Ovary Syndrome (PCOS): Bridging Gaps in Research and Practice
(2026) · Frontiers research topics · doi:10.3389/978-2-8325-7544-4
Fajr, M., Ahmadi, A., Rahbarghazi, R., Tamadon, A., & Mahdipour, M. (2026) · Tissue and Cell · doi:10.1016/j.tice.2026.103548
Huzna, N. C., Maulana, R. F., Deswindra, M. R., Saputra, G. A., Megawati, M., & Pratama, M. R. (2026) · Majalah Obstetri & Ginekologi · doi:10.20473/mog.v34i12026.42-52
Editorial: Polycystic ovarian syndrome in adolescence
Sharma, R. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1857004
“Globally, PCOS is emerging as a major public health issue with rising healthcare expenditure related to its long-term chronic complications (3).”
Sharma, R., Marwaha, R. K., Arya, A. K., Paharia, K., Saha, A., Gupta, P., Saini, H., & Sati, H. C. (2026) · Endocrine · doi:10.1007/s12020-026-04668-7
“It is associated with significant long-term morbidity including infertility, metabolic complications (hyperinsulinemia, type 2 diabetes, hypertension, metabolic syndrome and cardiovascular disease) and psychological distress with high associated health-care costs [2].”
The mechanism of Huanglian-Wendan decoction in treating PCOS-IR based on PI3K-AKT-GSK3 pathway
Wen, Y., Chang, H., Liu, L., Zhang, D., & Wang, M. (2026) · Journal of Radiation Research and Applied Sciences · doi:10.1016/j.jrras.2026.102469
Wang, X., (301752), K. Z., Hao, J., Zhao, M., Wang, X., & Xu, L. (2026) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2026.112836
Hammad, S. S., AbuLaban, A. R., & Abudawood, R. R. (2026) · International Journal of Clinical Practice · doi:10.1155/ijcp/4214280
Exploring the Relationship Between Hormonal Imbalance and Symptoms in PCOS
Jaber, Z. B. (2026) · International Journal of Biological and Biomedical Research · doi:10.54660/ijbbr.2026.2.3.52-55
Sisser, P., Sheppard, C., Sevchik, A., Barnes, S., Rao, M., Gilmore, N., Reddy, P., Kudeviz, S., Knecht, M., Sacca, L., et al. (2026) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-026-00479-9
Cardiometabolic and Pregnancy-Related Complications in PCOS
Cardozo, L. L. Y., Abdelhameed, A. M., Eissa, M., & Romero, D. G. (2026) · Physiology in health and disease · doi:10.1007/978-3-032-26472-5_14
Kashyap, P., Virvikram, Singh, B., Saini, G., Mandal, J. K., & Barwal, P. (2026) · BIO Web of Conferences · doi:10.1051/bioconf/202624900003
Namdev, I. (2026) · International Journal of Research and Innovation in Applied Science · doi:10.51584/ijrias.2026.11070204
Homoeopathic management of PCOS with a single remedy: A case report of natrum muriaticum
Devi, S., & Srivastava, M. (2026) · International Journal of Homoeopathic Sciences · doi:10.33545/26164485.2026.v10.i8.f.3131
Magnavita, N. (2026) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph23091138
Nowakowski, Ł., Warchoł, K., Kuźniar, A., Zimoń, B., Skoczylas, M. M., Marzec, P., Krawczyk, G., Jegorow, D., Pankiewicz, R., Warchol, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15176705
“…patient per year in various countries (direct + productivity loss) [157,162] Total economic cost of PCOS/PMOS in the US ~$7.9 billion annually [163,167] In the US, total social costs increase to ~$41–42 billion annually in 2022 [165,168] Direct medical costs Cost of treatment and diagnostics:…”
InfluentialTGFβ1 Gene Polymorphism and Serum TGF-β1 Levels in Women with Polycystic Ovary Syndrome
Washel, W. G. (2026) · Journal of Obstetrics Gynecology and Cancer Research · doi:10.24200/jogcr.11.11.1082
Patil, A., Barathe, R., Tate, D. M., Tate, D. M., Shishir, P., Gawande, N., More, A., Mahadik, S., Singhvi, R., & Berde, K. (2026) · International Journal of Advanced Research · doi:10.21474/ijar01/24090
Health utility, work productivity, and total economic burden of polycystic ovary syndrome
Amiri, M., Huang, Y., Thai, L., Ottey, S., Patterson, W., Delau, O. R., Yadav, S., Soucie, K. M., Partridge, T., Buyalos, R. P., et al. (2026) · Journal of the Endocrine Society · doi:10.1210/jendso/bvag217
“…to specific PCOS-/PMOS-related conditions, including reproductive care, pregnancy complications, T2DM, stroke, mental health disorders, and endometrial cancer (10, 13, 39, 40), no study has simultaneously measured the intangible and indirect costs of PCOS/PMOS in a single controlled comparison.”
Self-citationJi, P., Sun, S., Xu, X., & Chen, S. (2026) · International Journal of Women s Health · doi:10.2147/ijwh.s638672
“1,4,5 Despite extensive research, the molecular mechanisms that initiate and sustain ovarian dysfunction in PCOS remain incompletely understood, and current management remains largely symptom-oriented with limited mechanism-based therapeutic options.”
Zhuang, M., Zongnan, L. I. U., Yan, H., Mingyue, Y. I. N., ZHANG, Y., & Donglin, S. H. I. (2026) · Journal of Zhejiang University (Medical Sciences) · doi:10.3724/zdxbyxb-2026-0084
Metadata
- Authors
- Azziz, R., Marin, C., Hoq, L., Badamgarav, E., & Song, P.
- Affiliations
- Cedars-Sinai Medical Center (US)
- ORCID
- Azziz, Ricardo
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2005-08
- Volume
- 90
- Issue
- 8
- Pages
- 4650-4658
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2118575626
- Cited by
- 537
- References
- 90
- Citations by year
- 2026: 20 · 2025: 30 · 2024: 29 · 2023: 28 · 2022: 36 · 2021: 45 · 2020: 25 · 2019: 41 · 2018: 27 · 2017: 27 · 2016: 22 · 2015: 20 · 2014: 27 · 2013: 24 · 2012: 26
- FWCI
- 18.99
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Public Health Service (K24-D01346)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD029364, R01-HD29364)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Reproductive Health and Technologies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Keywords
- polycystic ovary syndrome, economic burden, health care costs, women of reproductive age, infertility treatment, hirsutism, abnormal uterine bleeding, menstrual disorders, PCOS screening, cost estimation
- MeSH terms
- Adolescent, Adult, Female, Humans, Polycystic Ovary Syndrome, United States, Incidence, Prevalence, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.